skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Review

(2907) Views  (550) Full article downloads

Authors: Michael J Prematta, Tracy Prematta, Timothy J Craig

Published Date August 2008 Volume 2008:4(5) Pages 975 - 982
DOI: http://dx.doi.org/10.2147/TCRM.S3172

Michael J Prematta, Tracy Prematta, Timothy J Craig

Section of Allergy and Immunology, Penn State University, Milton S. Hershey Medical Center, PA, USA

Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA.

Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks.

Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate.

Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate – many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years.

Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

Keywords: hereditary angioedema, c1 inhibitor, c1 esterase inhibitor, hereditary angioedema treatment








Readers of this article also read:

Docetaxel in the treatment of squamous cell carcinoma of the head and neck
Smoking cessation: an economic analysis and review of varenicline
Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
Cinryze™ as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
Management of acute attacks of hereditary angioedema: potential role of icatibant
Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumonia
Erratum
Who would benefit from memory training? A pilot study examining the ceiling effect of concurrent cognitive stimulation
Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs
Use of administrative hospital registry data and a civil registry to measure survival and other outcomes after cancer